Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study

Trial Profile

Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors IRIS
  • Most Recent Events

    • 08 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top